6.1 CONCLUSÃO:
Podemos concluir, considerando a metodologia utilizada bem como os testes estatísticos empregados, que na dose de 25 unidades, aplicada nas regiões frontal e temporal em pontos específicos e utilizando uma diluição que gera uma concentração de 25 unidades por ml, a Toxina Botulínica não reduziu significativamente a intensidade, nem a freqüência de cefaléia em pacientes portadores exclusivamente de migrânea sem aura. Apesar de não haver redução no nível da cefaléia (intensidade) nem na freqüência das crises, a TB na apresentação e dose utilizadas mostrou-se segura e livre de efeitos adversos.
BIBLIOGRAFIA CONSULTADA
ADAMS, R. D. VICTOR, M. ROPPER, A.H. Principles of Neurology. Sixty Edition, New York, 1997.
ALAM, M.; ARNDT, K.A.; DOVER, J.S. Severe, Intractable Headache after Injection with Botulinum a Exotoxin: Report of 5 cases. Journal of the Academy of
Dermatology. 46 (1). January, 2002.
AOKI, K. R. Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management. Headache. 43 (Suppl 1: S9-S15). Jul, 2003.
BEHMAND, R. et al. Single-Site Botulinum Toxin Type A Injection for Elimination of Migraine Trigger Points. Headache. 43:1085-1089. nov/dec, 2003.
BIGAL, M. E. et al. New Migraine Preventive Options: an Update with Pathophysiological Considerations. Rev Hosp Clin. 57 (6), 2002.
BINDER, W.J. et al. Botulinum Toxin Type A (BOTOX) for treatment of migraine.
Disease-A-Month. 48 (5), may, 2002.
BURSTEIN R, YARNITSKY D, GOOR-ARYEH I, RANSIL BJ, BAJWA ZH. An association between migraine and cutaneous allodynia. Annals of Neurology 2000;47:614-624.
BLUMENFELD, A. M. Botulinum Toxin Type A as an Effective Prophylactic Treatment in Primary Headache Disorders. Headache. 43 (8):853-60. September, 2003.
BLUMENFELD, A M; DODICK, D W; SILBERSTEIN, S D; Botulinum Neurotoxin for the Treatment of Migraine and Other Primary Headache Disorders. Dermatologic
Clinics. 22 (2). April, 2004.
CARRUTHERS, A. Botulinum Toxin Type A: History and Current Use in Upper Face.
Disease-A-Month. 48(5), may, 2002.
CUI, M. et al. Subcutaneous Administration of Botulinum Toxin A Reduces Formalin- Induced. Pain. 107(1-2):125-33. Jan, 2004.
CUTRER, F.M. Update on Migraine Pathogenesis. Syllabi. American Academy of Neurology, 56th Annual Meeting. April, 2004. 1 CD-ROM.
DODICK, D.W. Acute and Prophylactic Management of Migraine. Clinical
Cornerstone. 4 (3), Jan, 2001.
DODICK, D.W. Botulinum Neurotoxin for the Treatment of Migraine and Other Primary Disorders: From Bench to Bedside. Headache. 43 [Suppl 1]:S25-S33. july/aug, 2003.
DODICK, D. W. Botulinum Neurotoxin for the Treatment Of Headache And Myofascial Pain. Syllabi. American Academy of Neurology, 56th Annual Meeting. April, 2004. 1 CD-ROM
DURHAM, P. L. Regulation of Calcitonin Gene-Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy. Headache. 44 (1): 35-42. Jan, 2004.
EQUIPE EDITORIAL BIBLIOMED. Enxaqueca. Net Sessão Artigo Médico : Clínica Médica, 27 de outubro de 2003. Disponível em <http://www.bibliomed.com.br/lib/ShowCat.cfm?LibCatID=20031&CurrentPage=1&C urrentPage=2>. Acesso em 04/11/2003.
EVERS, S. Treatment of Headache with Botulinum Toxin A – A Review according to Evidence Medicine Criteria. Cephalalgia. 22(9):699-710. Nov , 1, 2002.
EVERS, S. Is There a Role for Botulinum Toxin in the Treatment of Migraine? Curr
Pain Headache Rep. 7 (3): 229-34. june, 2003.
EVERS, S. Botulinum Toxin and the Management of Chronic Headaches. Curr Opin
Otolaryngol Head Neck Surg. 12 (3): 197-203. Jun 1, 2004.
EVERS, S. et al. Botulinum Toxin A in the Prophylactic Treatment of Migraine - a Randomized, Double-Blind, Placebo-Controlled Study.
Cephalalgia. 24(10):838-43. Oct , 2004 .
FLETCHER, R. H. et al. Epidemiologia Clínica. 3ª edição. Porto Alegre. Ed. Artes médicas. 1996.
FREUND, B. J.; SCHWARTZ, M. Treatment of Chronic Cervical-Associated Headache with Botulinum Toxin A: a Pilot Study. Headache. 40(3):231-236, mar, 2000.
GOADSBY, P.J. LIPTON, R.B. FERRARI, M.D. Migraine – Current Understanding and Treatment. N Engl J Med 346 (4): 257-270, 2002.
GÖBEL, H. Botulinum Toxin in Migraine Prophylaxis. J Neurol. 251(suppl 1):I8-I11, 2004.
HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNACIONAL HEADACHE SOCIETY. The Internacional Classification of Headache Disorders (second edition). Cephalalgia 24 : suppl 1: 1-160 , 2004.
KLEIN, A. W. Complications with the Use of Botulinum Toxin. Dermatologic Clinics. 22 (2). April, 2004.
LANG, A.M. Botulinum Toxin Type A Therapy in Chronic Pain Disorders. Arch Phys
MACHADO, A. Neuroanatomia Funcional. Livraria Atheneu, 1988.
MD CONSULT. Botulinum Toxin. Net. Disponível em <http://www.mdconsult.com>. Acesso em abril de 2004.
MATHEW, N.T.; KAUP, A. O. The Use of Botulinum Toxin Type A in Headache Treatment. Curr Treat Options Neurol. 4(5):365-373. Sep, 2002.
MOORE, P.; NAUMANN,M. Handbook of Botulinum Toxin Treatment. Second ed. Massachusetts. BlackWel Science, 2003.
MUNCHAU,A.; BHATIA, K.P. Uses of botulinum toxin injection in medicine today. Br
Med J 320(7228):161-165. january, 2000
OLESEN, J. et al. Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. N Engl J Med 350(11):1004-10, 2004. POULAIN, B.; HUMEAU, Y. Le Mode D’action des Neurotoxines Botuliques: Aspects Pathologiques, Cellulaires et Moléculaires. Annales de réadaptation et de
médecine physique. 46: 265-275, 2003.
RAJ, P.P. Botulinum Toxin Therapy in Pain Management. Anesthesiology clinics of
Noth America. 21 (4). Dec, 2003.
RUSSELL, M.B. Genetics of migraine without aura, migraine with aura, migrainous disorders, head trauma migraine without aura and tension type headache.
Cephalalgia. 21 (7):778-80, 2001
SCHREIBER, C.P. The Pathophysiology of Primary Headache. Primary Care;
Clinics in Office Practice. 31 (2) june, 2004.
SILBERSTEIN, S. D; et al. Botulinum Toxin Type A as a Migraine Preventive Treatment. Headache. 40 (6):445-450. june; 2000.
SILBERSTEIN, S. D.; WELCH, M. Syllabi. American Academy of Neurology, 55th Annual Meeting. April, 2003. 1 CD-ROM.
SCHULTE-MATTLER, W. J.; KRACK, P. Treatment of Chronic Tension-type Headache with Botulinum Toxin A: a Randomized, Double-blind, Placebo-controlled Multicenter Study. Pain. 109: 110-114. 2004.
SMUTS, J.A. et al. Prophylact Treatment of Chronic Tension-Type Headache Using Botulinum Toxin Type A. European Journal of Neurology. 6 (suppl 4):S99-S102. 1999.
SMUTS, J.A.; BARNARD, P.W. Botulinum Toxin Type A in the Treatment of Headache Syndromes: a Clinical Report on 79 Patients. Cephalalgia 20:332, 2000. SUBCOMITÊ DE CLASSIFICAÇÃO DE CEFALÉIAS DA SOCIEDADE INTERNACIONAL DE CEFALÉIA. Classificação Internacional Das Cefaléias. –
SEGUNDA EDIÇÃO. Trad. Sociedade Brasileira de Cefaléia. São Paulo: Segmento
Farma Editores, 2004.
TJOLSEN, A., BERGE, O., HUNSKAAR, S. The Formalin Test: an evaluation of the method. Pain 51: 5-17, 1992.
TUCKER, T. et al. Hourglass Deformity After Botox Injection. Headache. 43 (5): 577 Abs S144. june, 2003.
VERHEYDEN, J.; BLITZER, A. Other Noncosmetic Uses Of BOTOX. Disease-A-
Month. 48 (5) may, 2002.
VOLCY-GOMEZ, M. [The Effectiveness and Safety of Botulinum Toxin in the Treatment of Chronic Primary Headaches][Article in Spanish]. Rev Neurol. 39(4):388-93. Aug 16-31, 2004